Home
Jan Gunnar Hatlebakk's picture

Jan Gunnar Hatlebakk

Professor
  • E-mailJan.Hatlebakk@uib.no
  • Visitor Address
    Haukeland Universitetssykehus Laboratoriebygget, 7. etg. Heis øst
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2022). Irritable bowel syndrome patients who are not likely to respond to fecal microbiota transplantation. Neurogastroenterology and Motility. 1-7.
  • Show author(s) (2021). Ultrasound imaging for assessing functions of the GI tract. Physiological Measurement. 16 pages.
  • Show author(s) (2021). Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome. World Journal of Gastroenterology (WJG). 2219-2237.
  • Show author(s) (2021). Long-term effects of fecal microbiota transplantation (FMT) in patients with irritable bowel syndrome. Neurogastroenterology and Motility.
  • Show author(s) (2021). Gastroparesis symptoms associated with intestinal hypomotility: An explorative study using wireless motility capsule. Clinical and Experimental Gastroenterology. 133-144.
  • Show author(s) (2020). The effect of supplementation with low doses of a cod protein hydrolysate on satiety hormones and inflammatory biomarkers in adults with metabolic syndrome: A randomized, double-blind study. Nutrients. 1-13.
  • Show author(s) (2020). Supplementation with low doses of a cod protein hydrolysate on glucose regulation and lipid metabolism in adults with metabolic syndrome: A randomized, double-blind study. Nutrients. 1-15.
  • Show author(s) (2020). Study protocol of the Bergen brain-gut-microbiota-axis study: A prospective case-report characterization and dietary intervention study to evaluate the effects of microbiota alterations on cognition and anatomical and functional brain connectivity in patients with irritable bowel syndrome. Medicine. 1-8.
  • Show author(s) (2020). Density of Musashi‑1‑positive stem cells in the stomach of patients with irritable bowel syndrome. Molecular Medicine Reports. 3135-3140.
  • Show author(s) (2020). Changes in fecal short-chain fatty acids following fecal microbiota transplantation in patients with irritable bowel syndrome. Neurogastroenterology and Motility.
  • Show author(s) (2019). Supplementation with cod protein hydrolysate in older adults: A dose range cross-over study. Journal of Nutritional Science (JNS). 1-8.
  • Show author(s) (2019). Overlapping of irritable bowel syndrome with erosive esophagitis and the performance of Rome criteria in diagnosing IBS in a clinical setting. Molecular Medicine Reports. 787-794.
  • Show author(s) (2019). Nasal and salivary pepsin as a biomarker for gastro-esophageal reflux in chronic rhinosinusitis. Rhinology Online. 25-31.
  • Show author(s) (2019). Increasing the Dose and/or Repeating Faecal Microbiota Transplantation (FMT) Increases the Response in Patients with Irritable Bowel Syndrome (IBS). Nutrients.
  • Show author(s) (2019). How to select patients for antireflux surgery? The ICARUS guidelines (international consensus regarding preoperative examinations and clinical characteristics assessment to select adult patients for antireflux surgery). Gut. 1928-1941.
  • Show author(s) (2019). Gastric emptying of low- and high-caloric liquid meals measured using ultrasonography in healthy volunteers. Ultrasound International Open. E27-E33.
  • Show author(s) (2019). Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study . Gut. 1-9.
  • Show author(s) (2019). Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut.
  • Show author(s) (2019). Effects of a Cod Protein Hydrolysate Supplement on Symptoms, Gut Integrity Markers and Fecal Fermentation in Patients with Irritable Bowel Syndrome. Nutrients. 1-13.
  • Show author(s) (2019). Diet in Irritable Bowel Syndrome (IBS): Interaction with Gut Microbiota and Gut Hormones. Nutrients. 1-15.
  • Show author(s) (2019). Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels. Scandinavian Journal of Gastroenterology. 690-699.
  • Show author(s) (2019). Acute effect of a cod protein hydrolysate on postprandial acylated ghrelin concentration and sensations associated with appetite in healthy subjects: a double-blind crossover trial. Food & Nutrition Research. 1-9.
  • Show author(s) (2018). The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation. PLOS ONE. 1-17.
  • Show author(s) (2018). The effect of a controlled gluten challenge in a group of patients with suspected non-coeliac gluten sensitivity: A randomized, double-blind placebo-controlled challenge. Neurogastroenterology and Motility. 1-10.
  • Show author(s) (2018). Navigated retrograde endoscopic myotomy (REM) for the treatment of therapy-resistant achalasia. Neurogastroenterology and Motility. 6 pages.
  • Show author(s) (2018). Effect of a cod protein hydrolysate on postprandial glucose metabolism in healthy subjects: A double-blind cross-over trial. Journal of Nutritional Science (JNS). 9 pages.
  • Show author(s) (2017). The dynamics of the oesophageal squamous epithelium `normalisation´ process in patients with gastro-oesophageal reflux disease treated with long-term acid suppression or anti-reflux surgery. Alimentary Pharmacology and Therapeutics. 1339-1349.
  • Show author(s) (2017). Interaction between diet and gastrointestinal endocrine cells. Biomedical Reports. 651-656.
  • Show author(s) (2017). Gastro-oesophageal reflux in patients with chronic rhino-sinusitis investigated with multichannel impedance - pH monitoring. Rhinology. 27-33.
  • Show author(s) (2017). Gastric accommodation in healthy subjects studied by ultrasound, manometry, and impedancemetry. Neurogastroenterology and Motility. 1-9.
  • Show author(s) (2017). Enteroendocrine, Musashi 1 and neurogenin 3 cells in the large intestine of Thai and Norwegian patients with irritable bowel syndrome. Scandinavian Journal of Gastroenterology. 1331-1339.
  • Show author(s) (2017). Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome. Neurogastroenterology and Motility. 1-9.
  • Show author(s) (2017). Effects of omeprazole or anti-reflux surgery on lower oesophageal sphincter characteristics and oesophageal acid exposure over 10 years. Scandinavian Journal of Gastroenterology. 11-17.
  • Show author(s) (2017). Chromogranin A cell density in the large intestine of Asian and European patients with irritable bowel syndrome. Scandinavian Journal of Gastroenterology. 691-697.
  • Show author(s) (2017). Abnormal differentiation of stem cells into enteroendocrine cells in rats with DSS-induced colitis. Molecular Medicine Reports. 2106-2112.
  • Show author(s) (2016). Gastroesophageal Acid Reflux Control 5 Years After Antireflux Surgery, Compared With Long-term Esomeprazole Therapy. Clinical Gastroenterology and Hepatology. 678-685.e3.
  • Show author(s) (2016). Changes in enteroendocrine and immune cells following colitis induction by TNBS in rats. Molecular Medicine Reports. 4967-4974.
  • Show author(s) (2016). Abnormalities in endocrine and immune cells are correlated in dextran‑sulfate‑sodium‑induced colitis in rats. Molecular Medicine Reports. 12-20.
  • Show author(s) (2015). Reduction in duodenal endocrine cells in irritable bowel syndrome is associated with stem cell abnormalities. World Journal of Gastroenterology (WJG). 9577-9587.
  • Show author(s) (2015). Peroral endoscopic pyloromyotomy for primary pyloric stenosis. Endoscopy.
  • Show author(s) (2015). Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: Data from the SOPRAN and LOTUS studies. Alimentary Pharmacology and Therapeutics. 1162-1174.
  • Show author(s) (2015). Long-term effect on symptoms and quality of life of maintenance therapy with esomeprazole 20 mg daily: A post hoc analysis of the LOTUS trial. Current Medical Research and Opinion. 65-73.
  • Show author(s) (2015). Densities of rectal peptide YY and somatostatin cells as biomarkers for the diagnosis of irritable bowel syndrome. Peptides. 12-19.
  • Show author(s) (2014). Stomach antral endocrine cells in patients with irritable bowel syndrome. International Journal of Molecular Medicine. 967-974.
  • Show author(s) (2014). Endocrine cells in the ileum of patients with irritable bowel syndrome. World Journal of Gastroenterology (WJG). 2383-2391.
  • Show author(s) (2014). Duodenal Chromogranin A Cell Density as a Biomarker for the Diagnosis of Irritable Bowel Syndrome. Gastroenterology Research and Practice. 8 pages.
  • Show author(s) (2014). Do patients with functional chest pain have neuroplastic reorganization of the pain matrix? A diffusion tensor imaging study. Scandinavian Journal of Pain. 85-90.
  • Show author(s) (2014). Amelioration of Severe TNBS Induced Colitis by Novel AP-1 and NF-κB Inhibitors in Rats. Scientific World Journal. 8 pages.
  • Show author(s) (2014). Abnormal rectal endocrine cells in patients with irritable bowel syndrome. Regulatory Peptides. 60-65.
  • Show author(s) (2013). Validation of the GerdQ questionnaire for the diagnosis of gastro-oesophageal reflux disease. Alimentary Pharmacology and Therapeutics. 564-572.
  • Show author(s) (2013). Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study. Scandinavian Journal of Gastroenterology. 1010-1017.
  • Show author(s) (2013). Low‑grade inflammation in the rectum of patients with sporadic irritable bowel syndrome. Molecular Medicine Reports. 1081-1085.
  • Show author(s) (2013). Evaluation of the usefulness of colonoscopy with mucosal biopsies in the follow-up of TNBS-induced colitis in rats. Molecular Medicine Reports. 446-450.
  • Show author(s) (2013). Colonoscopy with mucosal biopsies in young rats: A model for experimental gastroenterology. Molecular Medicine Reports. 1757-1760.
  • Show author(s) (2013). Chronic fatigue in patients with unexplained self-reported food hypersensitivity and irritable bowel syndrome: validation of a Norwegian translation of the Fatigue Impact Scale. Clinical and Experimental Gastroenterology. 101-107.
  • Show author(s) (2013). Changes in the symptom pattern and the densities of large-intestinal endocrine cells following Campylobacter infection in irritable bowel syndrome: a case report. BMC Research Notes. 11 pages.
  • Show author(s) (2013). Central response to painful electrical esophageal stimulation in well-defined patients suffering from functional chest pain. Neurogastroenterology and Motility. E718-E727.
  • Show author(s) (2013). Association between adherence to concomitant proton pump inhibitor therapy in current NSAID users and upper gastrointestinal complications. European Journal of Gastroenterology and Hepathology. 531-538.
  • Show author(s) (2012). The role of diet in the pathogenesis and management of irritable bowel syndrome (Review). International Journal of Molecular Medicine. 723-731.
  • Show author(s) (2012). Structured management strategy based on the Gastro-oesophageal Reflux Disease (GERD) Questionnaire (GerdQ) vs. usual primary care for GERD: pooled analysis of five cluster-randomised European studies. International journal of clinical practice. 897-905.
  • Show author(s) (2012). Randomised clinical trial: a comparison between a GerdQ‐based algorithm and an endoscopy‐based approach for the diagnosis and initial treatment of GERD. Alimentary Pharmacology and Therapeutics.
  • Show author(s) (2012). Randomised clinical trial: a comparison between a GerdQ-based algorithm and an endoscopy-based approach for the diagnosis and initial treatment of GERD. Alimentary Pharmacology and Therapeutics. 1290-1300.
  • Show author(s) (2012). Low Densities of Serotonin and Peptide YY Cells in the Colon of Patients with Irritable Bowel Syndrome. Digestive Diseases and Sciences. 873-878.
  • Show author(s) (2012). Irritable bowel syndrome: the role of gut neuroendocrine peptides. Frontiers in Bioscience-Elite (FBE). 2783-2800.
  • Show author(s) (2012). High densities of serotonin and peptide YY cells in the colon of patients with lymphocytic colitis. World Journal of Gastroenterology (WJG). 6070-6075.
  • Show author(s) (2012). Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial. Alimentary Pharmacology and Therapeutics. 959-971.
  • Show author(s) (2012). Chromogranin A cell density as a diagnostic marker for lymphocytic colitis. Digestive Diseases and Sciences. 3154-3159.
  • Show author(s) (2011). Structured management strategy versus usual care for gastroesophageal reflux disease: rationale for pooled anlysis of five European cluster-randomized studies. Therapeutic Advances in Gastroenterology. 11-26.
  • Show author(s) (2011). Laparoscopic Antireflux Surgery vs Esomeprazole Treatment for Chronic GERD The LOTUS Randomized Clinical Trial. Journal of the American Medical Association (JAMA). 1969-1977.
  • Show author(s) (2011). A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial. Gut. 1182-1188.
  • Show author(s) (2010). Sensation evoked by esophageal distension in functional chest pain patients depends on mechanical stress rather than on ischemia. Neurogastroenterology and Motility. 1170-+.
  • Show author(s) (2010). Mechanosensation and Mucosal Blood Perfusion in the Esophagus of Healthy Volunteers Studied with a Multimodal Device Incorporating Laser Doppler Flowmetry and Endosonography. Digestive Diseases and Sciences. 312-320.
  • Show author(s) (2010). Long-Term Outcome of Microscopic Esophagitis in Chronic GERD Patients Treated With Esomeprazole or Laparoscopic Antireflux Surgery in the LOTUS Trial. American Journal of Gastroenterology. 1015-1023.
  • Show author(s) (2010). Endoscopy in gastro-oesophageal reflux disease. Baillière's Best Practice & Research : Clinical Gastroenterology. 775-786.
  • Show author(s) (2009). Mucosal blood flow measurements using laser Doppler perfusion monitoring. World Journal of Gastroenterology (WJG). 198-203.
  • Show author(s) (2009). Management of gastro-oesophageal reflux disease in primary care: a European observational study. Current Medical Research and Opinion. 2777-2784.
  • Show author(s) (2009). Impact of gastroesophageal reflux disease on work absenteeism, presenteeism and productivity in daily life: a European observational study. Health and Quality of Life Outcomes. 7 pages.
  • Show author(s) (2009). Impact of gastroesophageal reflux disease on patients' daily lives: a European observational study in the primary care setting. Health and Quality of Life Outcomes. 8 pages.
  • Show author(s) (2009). Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. Clinical Gastroenterology and Hepatology. 1292-1298.
  • Show author(s) (2008). Standardization of surgical technique in antireflux surgery: The LOTUS trial experience. World Journal of Surgery. 995-998.
  • Show author(s) (2008). Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. Gut. 1207-1213.
  • Show author(s) (2008). Center for drug evaluation and research. Clinical white paper for the CDER-PHRMA-AASLD conference on drug-induced liver disease: A national and global problem. American Journal of Gastroenterology. 20-26.
  • Show author(s) (2007). Medical therapy of gastroesophageal reflux disease. Current Opinion in Gastroenterology. 434-439.
  • Show author(s) (2007). Advanced imaging and visualization in gastrointestinal disorders. World Journal of Gastroenterology (WJG). 1408-1421.
  • Show author(s) (2006). Novel developments in non-erosive and erosive gastroesophageal reflux disease. Current Opinion in Gastroenterology.
  • Show author(s) (2006). Dysphagia in the course of gastro-oesophageal reflux before surgery. Acta Endoscopica. 545-554.
  • Show author(s) (2006). A multimodal laser Doppler and endosonographic distension device for studying mechanosensation and mucosal blood flow in the oesophagus. Neurogastroenterology and Motility. 243-248.
  • Show author(s) (2005). Apotekpersonalets egenvurdering av kompetanse og faglig selvtillit. Norsk Farmaceutisk Tidsskrift. 17-20.
  • Show author(s) (2004). Endoscopic augmentation of the lower esophageal sphincter for the treatment of gastroesophageal reflux disease: Multicenter study of the gatekeeper reflux repair system. Endoscopy. 682-689.
  • Show author(s) (2004). Diagnostic approach to suspected irritable bowel syndrome. Baillière's Best Practice & Research : Clinical Gastroenterology. 735-746.
  • Show author(s) (2004). Behandling av gastroøsofageal refluks hos gravide. Tidsskrift for Den norske legeforening. 797-798.
  • Show author(s) (2000). Proton pump inhibitors: better before breakfast than without breakfast. Alimentary Pharmacology and Therapeutics. 1267-1272.
  • Show author(s) (2000). Oesophagusstriktur som komplikasjon til gastrøsofageal refluks hos barn. Tidsskrift for Den norske legeforening. 187-189.
  • Show author(s) (2000). Long-term management of gastro-oesophageal reflux disease with omeprazole or open anti-reflux surgery: results of a prospective, randomized clinical trial. European Journal of Gastroenterology and Hepathology. 879-887.
  • Show author(s) (2000). Gastric acidity and acid breakthrough on omeprazole 20mg b.i.d. or lansoprazole 30mg b.i.d. Alimentary Pharmacology and Therapeutics. 709-714.
  • Show author(s) (1999). Therapy for heartburn in primary care patients - an 8 weeks randomized double-blind study of omeprazole versus cisapride and placebo. BMJ. British Medical Journal. 550-553.
  • Show author(s) (1999). The effect of eradication of H.pylori on gastro-oesophageal reflux. Diseases of the esophagus. 915-920.
  • Show author(s) (1999). Spiromycin is comparable to oxytetracycline in eradicating H. pylori when given with ranititine bismuth citrate and metronidazole. Alimentary Pharmacology and Therapeutics. 651-659.
  • Show author(s) (1999). On demand therapy of reflux oesophagitis - a prospective study of symptoms, patient satisfaction and quality of life. Alimentary Pharmacology and Therapeutics. 1035-1040.
  • Show author(s) (1999). Medical therapy: Management of the refractory patient. Gastroenterology Clinics of North America. 847-860.
  • Show author(s) (1999). Lack of effect of acid suppression on gastric atrophy. Nordic GERD Study Group. Gastroenterology. 319-326.
  • Show author(s) (1999). Intragastric distribution and volume estimation of a liquid meal in patients with gastro-oesophageal reflux disease assessed by three-dimensional ultrasonography. Gut. 180.
  • Show author(s) (1999). Ineffective esophageal motility: the most common motility abnormality in patients with GERD-associated respiratory symptoms. American Journal of Gastroenterology. 1464-1467.
  • Show author(s) (1999). Effect of Omeprazole (PPI) on Ratio of Acid to Nonacid Gastroesophageal Reflux. Studies Using Simultaneous Intraesophageal Impedance and pH Measurement. Gastroenterology. G910.
  • Show author(s) (1999). Effect of Helicobacter pylori eradication on gastro-oesophageal reflux. Alimentary Pharmacology and Therapeutics. 915-920.
  • Show author(s) (1998). Outcome of open anti-reflux surgery as assessed in a Nordic multicentre, prospective clinical trial. The European Journal of Surgery. 751-757.
  • Show author(s) (1998). Obesity and gastroesophageal reflux. Motility. 4-6.
  • Show author(s) (1998). Gastroesophageal reflux in morbid obese patients treated with gastric banding or vertical banded gastroplasty. Annals of Surgery. 51-58.
  • Show author(s) (1998). Gastro-oesophageal reflux disease in primary care - an international study of different treatment strategies with omeprazole. European Journal of Gastroenterology and Hepathology. 119-124.
  • Show author(s) (1998). Endoscopic ultrasound - a new look at achalasia? European Journal of Gastroenterology and Hepathology. 543-545.
  • Show author(s) (1998). Dysphagia in the elderly: Diagnostic approach and clinical management. Clinical Geriatrics. 16-26.
  • Show author(s) (1998). Dilatation therapy for dysphagia in patients with upper esophageal sphincter dysfunction - manometric and symptomatic response. Diseases of the esophagus. 254-259.
  • Show author(s) (1998). Barretts øsofagus. Et økende problem. Tidsskrift for Den norske legeforening. 4100-4103.
  • Show author(s) (1997). The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease. Scandinavian Journal of Gastroenterology. 1100-1106.
  • Show author(s) (1997). Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole. Alimentary Pharmacology and Therapeutics. 1093-1099.
  • Show author(s) (1997). Lansoprazole 15 and 30 mg daily in maintenance therapy of reflux oesophagitis. Alimentary Pharmacology and Therapeutics. 365-372.
  • Show author(s) (1997). Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. Gut. 740-747.
  • Show author(s) (1997). Endoscopic grading of reflux oesophagitis: what observations correlate with gastro-oesophagal reflux? Scandinavian Journal of Gastroenterology. 760-765.
  • Show author(s) (1996). Pharmacokinetic optimisation in the treatment of gastrooesophageal reflux disease. Clinical Pharmacokinetics. 386-406.
  • Show author(s) (1996). Lansoprazole 15 and 30 mg daily in maintenanxe therapy of reflux oesophagitis. Alimentary Pharmacology and Therapeutics.
  • Show author(s) (1996). Gastro-oesophageal reflux during 3 months of therapy with ranitidine in reflux oesophagitis. Scandinavian Journal of Gastroenterology. 954-958.
  • Show author(s) (1996). Bismuth-based combination therapy for Heliobacter pylori-associated peptic ulcer disease (metronidazole for eradication, ranitidine for pain). American Journal of Gastroenterology. 935-941.
  • Show author(s) (1995). Spiramycin in triple therapy of Helicobacter pylori-associated peptic ulcer disease. An open pilot study with 12-month follow-up. Alimentary Pharmacology and Therapeutics. 197-200.
  • Show author(s) (1994). Ti dagers trippelkur for Helicobacter pylori-infeksjon og magesår: Status fire uker og ett år etter. Tidsskrift for Den norske legeforening. 2477-2479.
  • Show author(s) (1994). Ti dagers trippelkur for Helicobacter pylori-infeksjon og magesår: Status fire uker og ett år etter. Tidsskrift for Den norske legeforening. 2477-2479.
  • Show author(s) (1994). Prokinetica ved reflukssykdom. Virkningsmekanismer og klinisk effekt. Tidsskrift for Den norske legeforening. 689-692.
  • Show author(s) (1994). Konferanserapport Digestive diseases WEEK 1994. Therapia medica.
  • Show author(s) (1993). Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial. Scandinavian Journal of Gastroenterology. 224-228.
Academic lecture
  • Show author(s) (2021). Kort- og langtidseffekten av lav FODMAP-dietten på symptomer og kortkjedede fettsyrer hos pasienter med irritabel tarmsyndrom.
  • Show author(s) (2020). Short and extended effects of a low FODMAP diet on symptoms and short-chained fatty acids in patients with irritable bowel syndrome.
  • Show author(s) (2020). Long-term effects of faecal microbiota transplantation (FMT) in patients with irritable bowel syndrome.
  • Show author(s) (2020). Kvalitetsevaluering av tverrfaglig IBS-poliklinikk .
  • Show author(s) (2020). Kort- og langtidseffekten av lavFODMAP-diett på symptomer og mikrobiota hos pasienter med IBS .
  • Show author(s) (2020). Chromoendoscopy with Iodine-Potassium iodine solution in eosinophilic esophagitis.
  • Show author(s) (2019). Mage-tarmskolen – tverrfaglig internetbehandling ved Irritabel tarmsyndrom .
  • Show author(s) (2019). Effect of faecal microbiota transplantation on gut microenvironment and symptoms in patients with irritable bowel syndrome.
  • Show author(s) (2019). CHROMOENDOSCOPY WITH IODINE-POTASSIUM IODINE SOLUTION IN EOSINOPHILIC ESOPHAGITIS.
  • Show author(s) (2017). Navigated Retrograde Endoscopic Myotomy (REM) for the Treatment of Therapy-Resistant Achalasia.
  • Show author(s) (2016). Low FODMAP diet alters symptoms, microbiota, short-chain fatty acids and cytokine profiles in patients with IBS: A randomized controlled trial.
  • Show author(s) (2016). Low FODMAP diet alters symptoms, microbiota, short-chain fatty acids and cytokine profiles in patients with IBS: A randomized controlled trial.
  • Show author(s) (2015). Per Oral Endoskopisk Pyloromyotomi (POP) for primær pylorusstensose.
  • Show author(s) (2014). Per Oral Endoskpoisk Myotmi (POEM) for behandling av akalasi.
  • Show author(s) (2013). Endoskopisk behandling av tidlig spiserøreskreft.
  • Show author(s) (2000). Intragastric maldistribution in patients with reflux oesophagitis studied by an accurate 3D ultrasound system.
  • Show author(s) (2000). Evaluation of a symptomatic score for the diagnosis of GERD.
  • Show author(s) (1998). On demand therapy of reflux oesophagitis: a study of symptoms, patient satisfaction and quality of life.
  • Show author(s) (1996). Utredning av ikke-kardiale brystsmerter.
  • Show author(s) (1996). Transient LES-relaksasjon ved reflukssykdom.
  • Show author(s) (1994). Lansoprazole and amoxicillin oral suspension in the treatment of peptic ulcer disease.
  • Show author(s) (1994). Follow-up on 227 Patients with Peptic Ulcer Disease One Year after Eradication of Helicobacter Pylori.
  • Show author(s) (1993). Lansoprazole in the treatment of reflux oesophagitis: A survey of clinical studies.
Editorial
  • Show author(s) (2017). Editorial: the diminishing returns of normalisation of the oesophageal mucosa-Authors' reply. Alimentary Pharmacology and Therapeutics. 73-74.
Book review
  • Show author(s) (2021). Minneord: Arnold Berstad (1940-2020). Tidsskrift for Den norske legeforening. 293-293.
Popular scientific article
  • Show author(s) (2014). Per Oral Endoksopisk Myotomi (POEM)for akalasi. NFG-nytt. 4 pages.
  • Show author(s) (2013). Correct use of proton pump inhibitors for gastro-oesophageal reflux disease. Tidsskrift for Den norske legeforening. 43-46.
Feature article
  • Show author(s) (2000). Heartburn treatment in primary care. Letter to the editor. BMJ. British Medical Journal. 1406.
Doctoral dissertation
  • Show author(s) (2021). Supplementation with cod protein hydrolysate: Intervention studies in healthy adults and adults with metabolic syndrome.
  • Show author(s) (2020). Health effects of supplementation with cod protein hydrolysate: Impact on glucose metabolism and appetite in healthy subjects and gut health in irritable bowel syndrome.
  • Show author(s) (2010). Esophageal pain sensation during bag distention - biomechanical or ischemic in origin? : studied by a multi-modal device incorporating laser Doppler flowmetry, endosonography, manometry, and bag distension.
  • Show author(s) (1997). Diagnosis and treatment of uncomplicated reflux oesophagitis. -.
Academic chapter/article/Conference paper
  • Show author(s) (2013). Diet and Irritable Bowel Syndrome, with a Focus on Appetite-Regulating Gut Hormones. 13 pages.
  • Show author(s) (2005). Ultrasound in Patients with Gastroesophageal Reflux Disease. 30 pages.
  • Show author(s) (1993). Verdi av pH-måling og manometri status 1993. 9 pages.
Abstract
  • Show author(s) (2021). Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome. United European Gastroenterology journal. 635-636.
  • Show author(s) (2020). Long-term effects of faecal microbiota transplantation (FMT) in patients with irritable bowel syndrome. United European Gastroenterology journal. 46-46.
  • Show author(s) (2020). Changes in fecal short-chain fatty acids (SCFA) following fecal microbiota transplantation (FMT) in patients with irritable bowel syndrome (IBS). Neurogastroenterology and Motility.
  • Show author(s) (2018). Interdisciplinary self- help intervention for IBS - eHealth and patient education. Neurogastroenterology and Motility. 182-183.
  • Show author(s) (2018). Effects of faecal microbiota transplantation on gut microenvironment and symptoms in patients with irritable bowel syndrome. Neurogastroenterology and Motility. 178-179.
  • Show author(s) (2017). The effect of a controlled gluten challenge in patients with suspected non-coeliac gluten sensitivity: A randomized, double-blind placebo-controlled challenge. Clinical Nutrition. 32-33.
  • Show author(s) (2017). Gluten causes symptom relapse in a small group of patients with suspected non-celiac gluten sensitivity: A randomized, double-blind placebo controlled challenge. Neurogastroenterology and Motility. 68-69.
  • Show author(s) (2017). Effect of faecal microbiota transplantation on the symptoms and gut microbiota in patients with irritable bowel syndrome (IBS). Neurogastroenterology and Motility. 73-74.
  • Show author(s) (2017). Effect of faecal microbiota transplantation on gut bacterial fermentation products in patients with irritable bowel syndrome. United European Gastroenterology journal. A563-A564.
  • Show author(s) (2016). The Gastric Accomodation Reflex Studied by Ultrasound, Manometry and Impedancemetry in a Pilot Study. United European Gastroenterology journal. 675-675.
  • Show author(s) (2016). Low FODMAP diet alters symptoms, microbiota, short-chain fatty acids and cytokine profiles in patients with IBS: A randomized controlled trial. United European Gastroenterology journal. A101-A101.
  • Show author(s) (2016). Kinetics of microbial community composition in patients with diarrhea-predominant irritable bowel syndrome following faecal microbiota transplantation. United European Gastroenterology journal. LB11-LB11.
  • Show author(s) (2016). Effect of fecal microbiota transplantation on the symptoms and duodenal enteroendocrine cells in patients with irritable bowel syndrome. United European Gastroenterology journal. 677-677.
  • Show author(s) (2012). Duodenal mucosal lymphocyte subgroups in patients with persisting abdominal symptoms after Giardia lamblia infection. Neurogastroenterology and Motility. 172-172.
  • Show author(s) (2011). Low densities of serotonin and peptide YY cells in the colon of patients with irritable bowel syndrome. International Journal of Molecular Medicine. S10-S10.
  • Show author(s) (2010). Patients with functional chest pain have an increased oesophageal wall tone during bag distension. Scandinavian Journal of Gastroenterology. 45-45.
  • Show author(s) (2009). Mechanosensation and mucosal blood perfusion during bag distension in the esophagus in patients with functional chest pain. Scandinavian Journal of Gastroenterology. 38-38.
  • Show author(s) (2009). Changes in prescriptions dispensed for proton pump inhibitors (PPIs) following new restrictions on reimbursement - a nationwide Norwegian prescription database study. Scandinavian Journal of Gastroenterology. 39-39.
  • Show author(s) (2009). CHANGES IN PRESCRIPTIONS DISPENSED ON PROTON PUMP INHIBITORS (PPIS) FOLLOWING NEW RESTRICTIONS FOR REIMBURSEMENT - A NATIONWIDE NORWEGIAN PRESCRIPTION DATABASE STUDY. Value in Health. A58-A58.
  • Show author(s) (2007). Postprandial symptoms in healthy subjects improve in the left lateral supine position. Scandinavian Journal of Gastroenterology. 24-24.
Academic literature review
  • Show author(s) (2021). Current status of fecal microbiota transplantation for irritable bowel syndrome. Neurogastroenterology and Motility. 1-8.
  • Show author(s) (2019). Possible role of peptide YY (PYY) in the pathophysiology of irritable bowel syndrome (IBS). Nutrients. 1-7.
  • Show author(s) (2019). Pathophysiology of idiopathic gastroparesis and implications for therapy. Scandinavian Journal of Gastroenterology. 8-17.
  • Show author(s) (2017). Gastrointestinal neuroendocrine peptides/amines in inflammatory bowel Disease. World Journal of Gastroenterology (WJG). 5068-5085.
  • Show author(s) (2016). The possible role of gastrointestinal endocrine cells in the pathophysiology of irritable bowel syndrome. Expert Review of Gastroenterology & Hepatology. 139-148.
  • Show author(s) (2016). Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction-Recommendations of the Nordic Working Group. Scandinavian Journal of Pain. 111-122.
  • Show author(s) (2015). The relation between celiac disease, nonceliac gluten sensitivity and irritable bowel syndrome. Nutrition Journal.
  • Show author(s) (2014). Is irritable bowel syndrome an organic disorder? World Journal of Gastroenterology (WJG). 384-400.
  • Show author(s) (2014). Irritable bowel syndrome: recent developments in diagnosis, pathophysiology, and treatment. Expert Review of Gastroenterology & Hepatology. 435-443.
  • Show author(s) (2014). Interaction between ingested nutrients and gut endocrine cells in patients with irritable bowel syndrome (Review). International Journal of Molecular Medicine. 363-371.
  • Show author(s) (2014). Chronic constipation and treatment options (Review). Molecular Medicine Reports. 3-8.
  • Show author(s) (2013). The role of peptide YY in gastrointestinal diseases and disorders (Review). International Journal of Molecular Medicine. 275-282.
  • Show author(s) (2013). Gastroesophageal Reflux and Rhinosinusitis. Current Allergy and Asthma Reports. 218-223.
  • Show author(s) (2013). Clinical presentation, diagnosis, pathogenesis and treatment options for lymphocytic colitis (Review). International Journal of Molecular Medicine. 263-270.
  • Show author(s) (2012). Irritable bowel syndrome: treatment options. Clinical Practice. 591-600.
  • Show author(s) (2008). Clinical trial design in adult reflux disease: a methodological workshop. Alimentary Pharmacology and Therapeutics. 107-126.
Chapter
  • Show author(s) (2017). Sykdommer i øsofagus. 326-333. In:
    • Show author(s) (2017). Indremedisin I & II. Forlag Vett & Viten.

More information in national current research information system (CRIStin)